Azvudine

DB16407InvestigationalSmall molecule

Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

Mechanism: Azvudine is a nucleoside reverse transcriptase inhibitor that acts against HIV, HBV, and HCV. Some studies also show that it is able to modulate the expression of proteins like P-glycoprotein (P-gp), MRP2, and BCRP; in one instance, it was also able to increase the activity of P-gp. In 2020, the compound was tested in numerous clinical trials for the treatment of mild and common COVID-19.
Curator reviewed
Formula / weight: C₉H₁₁FN₆O₄ · 286.223 g/mol (avg)
Code names: FNC · HY-19314 · RO-0622 · SB17040

Resolves to

Compound

UNIIIJ2XP0ID0KCAS1011529-10-4ChEMBLCHEMBL519846

Structure

InChIKeyKTOLOIKYVCHRJW-XZMZPDFPSA-NSMILESNC1=NC(=O)N(C=C1)[C@@H]1O[C@@](CO)(N=[N+]=[N-])[C@@H](O)[C@@H]1F

Targets

Q72547polP0DTD1repQ9UNQ0ABCG2Q92887ABCC2P08183ABCB1

What you can answer from here — as of June 15, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Azvudine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account